Showing results (811-820 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 25, 2023
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phaseChan Zhang, Xinan Zhao, Zifeng Wang, et al.
Investigational New Drugs|December 1, 1988
Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (chip, JM9)]S P Chawla, B S Yap, D M Tenney, et al.
Investigational New Drugs|April 20, 2020
Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavirHuixin Yu, Julie M Janssen, Vincent A de Weger, et al.
Investigational New Drugs|August 23, 2025
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapySrikruthi Kunigal Sridhar, Kasim Sakran Abass, Buduru Gowthami, et al.
Investigational New Drugs|January 1, 1985
Homoharringtonine: a phase I evaluationJ A Stewart, I H Krakoff
Investigational New Drugs|January 1, 1985
A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group StudyE Eisenhauer, I Kerr, A Bodurtha, et al.
Investigational New Drugs|January 1, 1985
A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group StudyE Eisenhauer, I Quirt, J M Connors, et al.
Investigational New Drugs|February 15, 2023
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutationsAtsushi Osoegawa, Yohei Takumi, Takafumi Hashimoto, et al.
Investigational New Drugs|February 2, 2026
Scorpio fuscus venom as a promising anticancer agent against colorectal cancerSerdar Karakurt, Cigdem Gokcek-Sarac, Sinan Kandir, et al.
Investigational New Drugs|December 6, 2025
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 studyYasutoshi Kuboki, Nobuaki Matsubara, Hiromichi Nakajima, et al.
Pageof 372